CTOs on the Move

FemTec Health

www.femtechealth.com

 
Founded in May 2020 by Dr. Kimon Angelides and publicly launched in October 2021, FemTec Health is the leading Health and Beauty Sciences Company focused on women`s health. Angelides has brought together a female-led team with decades of experience across healthcare, wellness, and consumer products in public and private companies. FemTec Health`s mission is to revolutionize women`s healthcare by using state-of-the-art genomics, predictive intelligence, and digital technologies to create an experience that is unified, coordinated, and provides personalized services and products that are meaningful and effective for women. With offices in Houston, New York, San Diego, London, Barcelona, Athens & ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Southern Heritage Bank

Southern Heritage Bank is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Louisville, KY. To find more information about Southern Heritage Bank, please visit www.southernheritagebank.com

Iatroware

Iatroware is a Midland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hometown Health

Hometown Health is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InterGroup Services Corporation

InterGroup Services Corporation is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.